Abstract
To the Editor: The recent observation by Erbs et al1 that an intracoronary infusion of blood-derived progenitor cells (CPCs) improves LV function after recanalization of a chronic coronary total occlusion (CTO) may represent a new application of cellular therapy for ischemic heart disease. Twenty-six patients underwent PET and SPECT imaging to determine myocardial hibernation 8 days after successful recanalization of their CTO and then received CPCs (69 million; n=13) …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
